O

*click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Obeticholic acid, 5mg and 10mg film-coated tablets (Ocaliva®) SMC No (1232/17)	Primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid or as monotherapy in adults unable to tolerate ursodeoxycholic acid.	Available in line with National Guidance Formulary - under the direction of the liver clinic	162	Aug 2017
Obinutuzumab, 1,000mg, concentrate for solution for infusion (Gazyvaro®) SMC2015	Obinutuzumab in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma.	Not available as not recommended for use in NHS Scotland	171	Oct 2018
obinutuzumab, 1,000mg, concentrate for solution for infusion (Gazyvaro®) SMC No 1286/18	In combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma	Not available as not recommended for use in NHS Scotland	167	April 2018
Obinutuzumab (Gazyvaro®) (1219/17)	In combination with bendamustine followed by obinutuzumab maintenance, is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with rituximab or a rituximab-containing regimen.	Available in line with National Guidance	160	Apr 2017
Obinutuzumab (Gazyvaro®) (1008/14)	CLL	HOSPITAL ONLY (Haematology)	144	Jan/Feb 2015
Ocrelizumab 300mg concentrate for solution for	For the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of	Not routinely available as local clinical experts do not wish to add	179	Apr 2020

infusion (Ocrevus®) SMC 2223	disease duration and level of disability, and with imaging features characteristic of inflammatory activity.	the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Ocrelizumab 300mg concentrate for solution for infusion (Ocrevus®) SMC2121	The treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. SMC restriction: Treatment of relapsing remitting multiple sclerosis (RRMS) in adults with active disease defined by clinical or imaging features who are contra-indicated or otherwise unsuitable for alemtuzumab	Available in line with local guidance for prescribing	173	Mar 2019
Ocrelizumab 300mg concentrate for solution for infusion (Ocrevus®) SMC No 1344/18 Superseded by SMC 2121, see above	The treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. Two phase III studies identified superiority of ocrelizumab when compared with another disease modifying treatment in adult patients with relapsing forms of multiple sclerosis	Not available as not recommended for use in NHS Scotland	170	Sep 2018
Ocriplasmin (Jetrea®) (892/13)	In adults for the treatment of vitreomacular traction	Non Formulary - Absence of Clinician demand	140 130	July/Aug 2014 Sept/Oct 2013
odevixibat 200, 400, 600 and 1,200 microgram hard capsules (Bylvay®)	For the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	190	August 2022
Oestrogens, conjugated, bazedoxifene acetate (Duavive®) 0.45mg / 20mg modified-release tablets SMC No: 1220/17	Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate	Not available as not recommended for use in NHS Scotland	159	Feb 2017
Ofatumumab 100mg & 1000mg concentrate for solution for	Treatment of adult patients with relapsed CLL in combination with fludarabine and cyclosphosphamide.	Not available as not recommended for use in NHS Scotland	161	Jun 2017

infusion (Arzerra®) (1237/17)				
Ofatumumab 20mg/0.4ml solution for injection in pre-filled syringe/pen (Kesimpta®) SMC2357	Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. SMC restriction: treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.	Available in line with national guidance	186	Sept 2021
Ofatumumab (Arzerra®) (1037/15)	For the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy.	Non Formulary - lack of clinician support	148	May 2015
Ofatumumab (Arzerra®) (626/10)	CLL	Not recommended	99	Aug/Sept 2010
Olanzapine (ZypAdhera®) (624/10)	Schizophrenia	Not recommended	99	Aug/Sept 2010
Olanzapine (Zyprexa®)	Bipolar disorder		39	2004
Olanzapine (Zyprexa®)	Moderate to severe manic episode		27	2003
Olanzapine IM (Zyprexa®)	Agitation disturbed behaviour		44 42	2004
olaparib film-coated tablets (Lynparza®) SMC2737	monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy. Olaparib offers an additional treatment choice in the therapeutic class of poly (ADP-ribose) polymerase	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		

	(PARP) inhibitors. Another medicine within this therapeutic class has been accepted for use via the end of life medicine process.			
Olaparib film-coated tablets (Lynparza) SMC2518	As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have human epidermal growth factor receptor 2 (HER2)-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.	Available in line with national guidance	195	Dec 2023
Olaparib 100mg and 150mg film-coated tablets (Lynparza®) SMC2368	In combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability. In a phase III study, maintenance treatment with olaparib plus bevacizumab significantly prolonged progression-free survival (PFS) compared with placebo plus bevacizumab in patients with advanced ovarian cancer who responded to first-line standard therapy including bevacizumab.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	188	April 2022
olaparib 100mg and 150mg film-coated tablets (Lynparza®) SMC2435		Not available as not recommended for use in NHS Scotland	188	April 2022
olaparib 100mg and 150mg film-coated tablets (Lynparza®) SMC2436			188	April 2022
olaparib 100mg and 150mg film-coated tablets (Lynparza®)	Following a full submission assessed under the end of life and orphan equivalent medicine process	Available in line with national guidance	187	Dec 2021

SMC2366				
Olaparib 100mg and 150mg film-coated tablets (Lynparza®)SMC2367	As monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. SMC restriction: patients with BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.	Available in line with national guidance	186	Sept 2021
Olaparib 100mg and 150mg film-coated tablets (Lynparza®) SMC 2209	For the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.	Available in line with national guidance	178	Feb 2020
Olaparib 50mg hard capsules (Lynparza®) SMC No 1047/15	Monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy	Available in line with national guidance	150 158	June 2015 Dec 2016
olaparib (Lynparza) AstraZeneca UK Ltd SMC2617	In combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.	Available in line with national guidance	197	May/June 2024
Olaratumab 10mg/mL concentrate for solution for infusion (Lartruvo®) SMC No. 1273/17	In combination with doxorubicin for the treatment of adult patients with advanced soft-tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin	Available in line with national guidance	165	Jan 2018

Olipudase alfa powder for concentrate for solution for infusion (Xenpozyme®) Sanofi SMC2560	As an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B.	Available in line with national guidance	195	December 2023
Olmesartan medoxomil/amlodipine besilate/hydrochlorothiazide (Sevikar HCT®) (823/12)	Hypertension	Non-formulary - alternatives preferred	123	Jan 2013
Olmesartan medoxomil/amlodipine besilate/hydrochlorothiazide (Sevikar HCT®) (706/11)	Hypertension	Not recommended	111	Nov 2011
Olmesartan medoxomil/amlodipine (Sevikar®) (574/09)	Hypertension	Non-formulary	93	Oct/Nov 2009
Olmesartan (Olmetec®)	Hypertension	Non-formulary	36 33	2003
Olmesartan/hydrochlorothiazide (Olmetec Plus®)	Hypertension	Non-formulary	58	2006
Olodaterol (Striverdi® Respimat®) (974/14)	In adults for the treatment of vitreomacular traction	Awaiting specialist feedback Not recommended	145 140	Feb 2015 Jul/Aug 2014
Olopatadine hydrochloride 600 micrograms / mometasone furoate monohydrate 25 micrograms per actuation nasal spray (Ryaltris®)	In adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis. SMC restriction: for use where monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient. Olopatadine hydrochloride / mometasone furoate monohydrate (Ryaltris®) offers an additional treatment	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	188	April 2022

	choice of antihistamine and glucocorticoid in a single nasal spray. SMC has previously accepted an alternative antihistamine / glucocorticoid combination for use in allergic rhinitis.			
Olopatadine eye drops (Opatanol®)	Seasonal allergic conjunctivitis	Non-formulary	55 31	2006 2003
Omalizumab (Xolair®) (1017/14)	Chronic spontaneous urticaria	HOSPITAL ONLY (Dermatology)	145	Feb 2015
Omalizumab powder (Xolair®) (708/11)	Adults, adolescents (12 years of age and older) and children (6-<12 years of age) with convincing IgE medicated asthma.	HOSPITAL ONLY (Adult chest/rhinology & paediatric asthma clinics)	107	Jul 2011
Omalizumab powder (Xolair®) (611/10)	Add-on therapy to improve asthma control in children (6 to <12 years of age)	HOSPITAL ONLY (Paediatrics)	99 97 Protocol 96	June/Jul 2010 Apr/May 2010
Omalizumab (Xolair®)	Severe persistent allergic asthma	HOSPITAL ONLY (Chest or Rhinology Clinics)	75 Protocol 73 65 59	Dec 2007 Oct 2007 Jan 2007 2006
Ombitasvir/paritaprevir/ritonavir (Viekirax®) and dasabuvir (Exviera®) (1051/15)	For use in combination with dasabuvir (Exviera®) with or without ribavirin for the treatment of genotype 1 chronic hepatitis C (CHC) in adults and for use in combination with ribavirin for the treatment of genotype 4 CHC in adults.	Hospital Only Hepatitis Team Gastroenterology Specialist List	149	Jun/Jul 2015
Omega-3-acid ethyl esters (Omacor®)	Secondary prevention after MI		22	2002
Omega-3-acid ethyl esters (Omacor®)	Hypertriglyceridemia		22	2002
Onasemnogene abeparvovec 2 × 1013 vector genomes/mL	Treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and	Available from a specialist centre in another NHS Board	184	May 2021

solution for infusion (Zolgensma®) SMC2311	a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene. SMC restriction: for the treatment of - patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or - pre-symptomatic patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene, where patients are expected to develop SMA type 1 In a phase III study of patients with symptomatic SMA type 1 treated with onasemnogene abeparvovec, survival was significantly better than a historical control cohort. In addition, motor milestones achieved generally exceeded the natural history of SMA type 1.			
Ondansetron (Setofilm®) (912./13)	In adults: · prophylaxis of acute N & V induced by chemotherapy · prophylaxis and treatment of delayed N & V induced by chemotherapy · prophylaxis and treatment of acute and delayed N & V induced by radiotherapy · prophylaxis and treatment of post-opearative PONV. In paediatrics:	Formulary (Haematology/Oncology patients) Non-formulary - ondansetron liquid preferred. Paediatric ward and paediatric haematology/oncology clinic	132	Nov/Dec 2013
Opicapone 50mg hard capsules (Ongentys®) Bial Pharma UK Ltd SMC2430	As adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at	188	April 2022

	dose motor fluctuations who cannot be stabilised on those combinations.	this time or there is a local preference for alternative medicines.		
Opicapone 50mg hard capsules (Ongentys®) SMC No (1281/17)	Adjunctive therapy to preparations of levodopa / DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations	Not available as not recommended for use in NHS Scotland	164	Nov 2017
Oritavancin 400mg powder for concentrate for solution for infusion (Tenkasi®) SMC2285	Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. SMC restriction: patients with confirmed or suspected methicillin-resistant Staphylococcus aureus (MRSA) infection who are eligible for early discharge. Use should be on the advice of local microbiologists or specialists in infectious disease.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	189	May 2022
Oseltamavir 30mg, 45mg, 75mg capsules and 6mg/ml powder for oral suspension (Tamiflu®) 1127/16	Treatment of influenza in children aged <1 year including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community.	Available in line with National Guidance	154	May 2016
Osilodrostat (Isturisa) SMC2640	treatment of endogenous Cushing's syndrome in adults	Not available as not recommended for use in NHS Scotland	196	Feb 2024
Osimertinib (Tagrisso) AstraZeneca SMC2382	As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.	Available in line wth national guidance	188	April 2022
Osimertinib 40mg and 80mg film-coated tablets (Tagrisso®) SMC2383	As monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR)	Available in line with local guidance	188	April 2022

	exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations. SMC restriction: treatment with osimertinib is subject to a three-year clinical stopping rule. In a placebo-controlled phase III study, osimertinib significantly improved disease free survival (DFS) in patients with completely resected EGFR mutation-positive NSCLC.			
Osimertinib 40mg and 80mg film-coated tablet (Tagrisso®) SMC2171	As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations		177	Dec 2019
Osimertinib (Tagrisso®) (1214/17)	Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC).	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by June 2017	160	Apr 2017
Ospemifene 60mg film-coated tablets (Senshio®) SMC 2170	Treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	177	Dec 2019
Oxaliplatin (Eloxatin®)	Adjuvant treatment of stage III colon cancer		54	2005
Oxybutynin transdermal patch (Kentera®)	Overactive bladder		53	2005
Oxycodone injection (OxyNorm®) (648/10)	Moderate to severe cancer pain	GPs and hospital doctors may prescribe under the direction of Palliative Care/Oncology	102 100 45	Jan/Feb 2011 Oct/Nov 2010 2004
Oxycodone injection (OxyNorm®)	Post-operative pain		58	2006

Oxycodone/naloxone prolonged release (Targinact®) (541/09)	Severe pain	Not recommended	87	Mar 2009
Oxycodone prolonged release (OxyContin®)	Severe pain		53	2005
Ozanimod 0.23mg, 0.46mg and 0.92mg hard capsules (Zeposia®) SMC2478	For the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 2022
Ozanimod 0.23mg, 0.46mg and 0.92mg hard capsules (Zeposia®) SMC2309	Treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. SMC restriction: suitable for or requesting an oral treatment. In two phase III studies, ozanimod demonstrated a significantly greater reduction in annualised relapse rate compared with another disease-modifying treatment in patients with relapsing forms of multiple sclerosis.	Not routinely available as local clinical experts do not wish to add the medicine to the forulary at this time or there is a local preference for alternative medicines.	183	March 2021

Updated: 5th June 2025

Back to top Back to homepage